Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ANKTIVA FDA Approval: First-in-Class IL-15 Agonist for NMIBC - ImmunityBio
ImmunityBio Receives FDA Expanded Access Authorization for Landmark ...
PPF Group | ImmunityBio presented positive long-term OS data of Anktiva ...
IBRX | ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class ...
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 ...
ImmunityBio (IBRX) takes cancer fight to Saudi Arabia, and Wall Street ...
On this International Clinical Trials Day, we at ImmunityBio are ...
ImmunityBio bags maiden FDA nod for bladder cancer; Ipsen, Skyhawk ...
ImmunityBio reports positive ANKTIVA survival in NSCLC | Grafa
Immunotherapy by ImmunityBio - Cancer Vaccine Research
ImmunityBio converts from Immunomedics Message Board - Msg: 34307274
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for ...
ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer ...
ImmunityBio Receives FDA RMAT Designation to Achieve Reversal of ...
ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC ...
How ImmunityBio is transforming cancer treatment - in just 30 seconds ...
ImmunityBio Shares Surge 9.57% as FDA Seeks Data Resubmission for ...
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder ...
ImmunityBio Shares Surge: Time to Take Action? - StocksToTrade
ImmunityBio has reached many important milestones this year — we owe ...
ImmunityBio shares surge on updated durable lymphoma study results
ImmunityBio follows through in lung cancer | ApexOnco - Clinical Trials ...
ImmunityBio Advances Pipeline with Chemotherapy-Free Trial and ...
ImmunityBio (NASDAQ:IBRX) Reaches New 1-Year High - Should You Buy?
Can ImmunityBio Inoculate Its Future With Regulatory Wins?
ImmunityBio and Amyris conclude Covid-19 vaccine commercialisation JV
ImmunityBio releases data on Anktiva for non-small cell lung cancer
ImmunityBio Announces Key Milestone With ANKTIVA in BCG-Unresponsive ...
ImmunityBio Inc’s BLA for N-803 Progresses with FDA Submission
ImmunityBio Surges 12.45% on EMA's ANKTIVA Approval Recommendation ...
FDA to Study ImmunityBio Cancer Drug - Los Angeles Business Journal
ImmunityBio | El Segundo CA
ImmunityBio Secures FDA Approval for BLA for Bladder Cancer Drug, New ...
Patrick-Soon Shiong of ImmunityBio (IBRX) presents at Jefferies London ...
ImmunityBio partners with Serum Institute for BCG vaccines
ImmunityBio gains FDA authorisation for BCG alternative
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer ...
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances
ImmunityBio Stock: Buy Low Now Vs. Buy High Later (NASDAQ:IBRX ...
ImmunityBio - Thương hiệu nổi bật trong lĩnh vực công nghệ sinh học, 1 ...
ImmunityBio (IBRX) From Bladder Cancer to Lung Cancer: The Expanding ...
ImmunityBio Bags US FDA Nod For Anktiva to treat Patient with Bladder ...
ImmunityBio Inc. Drug Approved By FDA | News, Sports, Jobs - Post Journal
ImmunityBio Reports Encouraging Evidence That ANKTIVA Enhances Immune ...
ImmunityBio is honored to be recognized as one of FastCompany's most ...
全球首个IL-15药物获批！ImmunityBio的Anktiva获FDA批准用于治疗卡介苗不响应的非肌肉浸润性膀胱癌医药新闻-ByDrug ...
IBRX Garners Retail Attention On Positive Update In Immunotherapy For ...
ImmunityBio’s Anktiva + BCG Receives the MHRA’s Approval for BCG ...
ImmunityBio’s Anktiva Receives the US FDA’s Approval to Treat Non ...
FDA approves Anktiva, (N-803, or nogapendekin alfa inbakicept-pmln ...
ImmunityBio's ANKTIVA® Granted FDA Approval: Breakthrough IL-15 ...
FDA Grants RMAT for ImmunityBio's ANKTIVA® and CAR-NK in Reversal of ...
ImmunityBio, Inc. - Regulation FD Disclosure, Financial Statements and ...
The Interplay Between Innate and Adaptive Immunity in Mechanisms of ...
ImmunityBio: ANKTIVA Shows 21.1-Month Survival in Advanced Lung Cancer ...
FDA Approval of ANKTIVA (by ImmunityBio), First-in-Class IL-15 Receptor ...
ImmunityBio’s Visionary Approach to Cancer Immunotherapy
FDA Grants Expanded Access for ImmunityBio’s ANKTIVA to Treat ...
Our goal is to help patients outsmart their disease by strengthening ...
The EMA Accepts MAA for ImmunityBio’s Anktiva to Treat BCG-Unresponsive ...
ImmunityBio's Anktiva: A Breakthrough in Advanced NSCLC Treatment
ImmunityBio's Q1 2025 Surge: A Strategic Inflection Point in Immunotherapy
Schematic overview of the three layers of immune defense | BioRender ...
FDA Approves ImmunityBio's Anktiva for Bladder Cancer, Marking Major ...
ImmunityBio's Cancer BioShield: A New Frontier in Oncology and a ...
At ImmunityBio, we're making our investigational therapeutics available ...
ImmunityBio, Inc. (IBRX) Interactive Stock Chart - Yahoo Finance
The types of antibodies and cells that make our immune system
ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients
ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global ...
Understanding the Cancer-Immunity Cycle to Improve Cancer Immunotherapy ...
Immune System: Innate vs. Adaptive Immunity - Medical Laboratory ...
Global first IL-15 drug approved! ImmunityBio's Anktiva receives FDA ...
ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder ...
ImmunityBio: Anktiva’s Launch Demands A Reassessment (NASDAQ:IBRX ...
ImmunityBio’s Q1 Surge: A Pivotal Shift to Revenue Dominance in Oncology
ImmunityBio’s 2025 FDA Submissions After Agency Meeting
Medical Studies & Immunotherapies - Advanced Clinical Research
FDA accepts to review ImmunityBio’s BLA for bladder cancer treatment
FDA accepts BLA resubmission for ImmunityBio’s bladder cancer therapy ...
Types of immunity | PPTX
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo | BioWorld
New Insights into Bladder Cancer Treatment Could Help Improve ...
FDA Approves ImmunityBio’s Anktiva for the Treatment of BCG ...
How Is Immunotherapy Used to Treat Bladder Cancer? | Dana-Farber Cancer ...
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
ImmunityBio, Inc. on LinkedIn: ImmunityBio's mission is to address ...
ImmunityBio’s Lynch Syndrome Vaccine Trial – Small Cap Stocks
ImmunityBio: A Small Bet Is Warranted (NASDAQ:IBRX) | Seeking Alpha
US FDA approves ImmunityBio's bladder cancer therapy | Reuters
ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield Platform
How High Can IBRX Stock Go Now? Here’s What Wall Street Thinks After ...
10+ Active immunity Examples to Download
#immunitybio | ImmunityBio, Inc.
Immunity Boost Bundle — Biomedic Labs
ImmunityBio: Share Price Plummets, Time to Rethink?
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer ...
bio-immunity-ppt thanishka.pptx acquired immunity | PPTX
Immunity Bio: Anktiva Bladder Cancer Drug May Be Real Deal (NASDAQ:IBRX ...
